Abstract
Neuroblastoma (NB) is a heterogeneous tumor that is common in infants and young children. Long non-coding RNA X-inactive specific transcript (XIST) is implicated in NB advancement. Nevertheless, the role and regulatory mechanism by which XIST in NB are not fully elucidated. Expression levels of XIST, microRNA-375-5p (miR-375), and L1 cell adhesion molecular (L1CAM) were examined through quantitative real-time polymerase chain reaction (qRT-PCR). The cell cycle progression, proliferation, and colony formation of NB cells were determined with flow cytometry, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), or cell colony formation assays. Cell apoptotic rate was detected with flow cytometry assay. The relationship between XIST or L1CAM and miR-375 was verified via dual-luciferase reporter assay. The level of L1CAM protein was examined through western blotting. The role of XIST in vivo was confirmed through xenograft assay. XIST and L1CAM were upregulated while miR-375 was downregulated in NB tissues and cells. XIST depletion repressed tumor growth in vivo and elevated radiosensitivity, arrested cell cycle progression, and impeded proliferation of NB cells in vitro. Mechanistically, XIST modulated L1CAM expression through competitively binding to miR-375. Furthermore, miR-375 inhibitor recovered XIST inhibition-mediated effects on the radiosensitivity and malignant behaviors of NB cells. Also, L1CAM overexpression reversed the effects of miR-375 enhancement on the cell cycle progression, proliferation, and radiosensitivity of NB cells. XIST downregulation repressed tumor growth and boosted radiosensitivity of NB via modulating the miR-375/L1CAM axis, indicating that XIST was a promising target for NB treatment.
Similar content being viewed by others
References
Yu Y, Chen F, Yang Y, Jin Y, Shi J, Han S, Chu P, Lu J, Tai J, Wang S, Yang W, Wang H, Guo Y, Ni X (2019) lncRNA SNHG16 is associated with proliferation and poor prognosis of pediatric neuroblastoma. Int J Oncol 55(1):93–102
Swift CC, Eklund MJ, Kraveka JM, Alazraki AL (2018) Updates in diagnosis, management, and treatment of neuroblastoma. Radiographics 38(2):566–580
Kholodenko IV, Kalinovsky DV, Doronin II, Deyev SM, Kholodenko RV (2018) Neuroblastoma origin and therapeutic targets for immunotherapy. J Immunol Res 2018:7394268
Défachelles AS, Cougnenc O, Carpentier P (2011) Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications. Bull Cancer 98(5):559–569
Peng WX, Koirala P, Mo YY (2017) LncRNA-mediated regulation of cell signaling in cancer. Oncogene 36(41):5661–5667
Bhan A, Soleimani M, Mandal SS (2017) Long noncoding RNA and cancer: a new paradigm. Cancer Res 77(15):3965–3981
Renganathan A, Felley-Bosco E (2017) Long noncoding RNAs in cancer and therapeutic potential. Adv Exp Med Biol 1008:199–222
Dou Q, Xu Y, Zhu Y, Hu Y, Yan Y, Yan H (2019) LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein. Eur J Pharmacol 852:134–141
Zhang N, Zeng X, Sun C, Guo H, Wang T, Wei L, Zhang Y, Zhao J, Ma X (2019) LncRNA LINC00963 promotes tumorigenesis and radioresistance in breast cancer by sponging miR-324-3p and inducing ACK1 expression. Mol Ther Nucleic Acids 18:871–881
Wei W, Liu Y, Lu Y, Yang B, Tang L (2017) LncRNA XIST promotes pancreatic cancer proliferation through miR-133a/EGFR. J Cell Biochem 118(10):3349–3358
Chen D-L, Chen L-Z, Lu Y-X, Zhang D-S, Zeng Z-L, Pan Z-Z, Huang P, Wang F-H, Li Y-H, Ju H-Q, Xu R-H (2017) Long noncoding RNA XIST expedites metastasis and modulates epithelial-mesenchymal transition in colorectal cancer. Cell Death Dis 8(8):e3011
Zhu H, Zheng T, Yu J, Zhou L, Wang L (2018) LncRNA XIST accelerates cervical cancer progression via upregulating Fus through competitively binding with miR-200a. Biomed Pharmacother 105:789–797
Zheng R, Lin S, Guan L, Yuan H, Liu K, Liu C, Ye W, Liao Y, Jia J, Zhang R (2018) Long non-coding RNA XIST inhibited breast cancer cell growth, migration, and invasion via miR-155/CDX1 axis. Biochem Biophys Res Commun 498(4):1002–1008
Zhang J, Li W-Y, Yang Y, Yan L-Z, Zhang S-Y, He J, Wang J-X (2019) LncRNA XIST facilitates cell growth, migration and invasion via modulating H3 histone methylation of DKK1 in neuroblastoma. Cell Cycle 18(16):1882–1892
Di Leva G, Garofalo M, Croce CM (2014) MicroRNAs in cancer. Annu Rev Pathol 9:287–314
Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16(3):203–222
Xu X, Chen X, Xu M, Liu X, Pan B, Qin J, Xu T, Zeng K, Pan Y, He B, Sun H, Sun L, Wang S (2019) miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells. Aging (Albany NY) 11(18):7357–7385
Liu J, Wang P, Zhang P, Zhang X, Du H, Liu Q, Huang B, Qian C, Zhang S, Zhu W, Yang X, Xiao Y, Liu Z, Luo D (2019) An integrative bioinformatics analysis identified miR-375 as a candidate key regulator of malignant breast cancer. J Appl Genet 60(3–4):335–346
Sun X, Wei B, Peng Z-H, Fu Q-L, Wang C-J, Zheng J-C, Sun J-C (2019) Knockdown of lncRNA XIST suppresses osteosarcoma progression by inactivating AKT/mTOR signaling pathway by sponging miR-375-3p. Int J Clin Exp Pathol 12(5):1507–1517
Zhang H, Liu T, Yi S, Gu L, Zhou M (2015) Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation. Mol Oncol 9(7):1301–1311
Rathjen FG, Schachner M (1984) Immunocytological and biochemical characterization of a new neuronal cell surface component (L1 antigen) which is involved in cell adhesion. Embo J 3(1):1–10
Na'ara S, Amit M, Gil Z (2019) L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression. Oncogene 38(4):596–608
Corrado G, Laquintana V, Loria R, Carosi M, de Salvo L, Sperduti I, Zampa A, Cicchillitti L, Piaggio G, Cutillo G, Falcioni R, Vizza E (2018) Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. J Exp Clin Cancer Res 37(1):139
Wachowiak R, Krause M, Mayer S, Peukert N, Suttkus A, Müller WC, Lacher M, Meixensberger J, Nestler U (2018) Increased L1CAM (CD171) levels are associated with glioblastoma and metastatic brain tumors. Medicine (Baltimore) 97(38):e12396
Rached J, Nasr Z, Abdallah J, Abou-Antoun T (2016) L1-CAM knock-down radiosensitizes neuroblastoma IMR-32 cells by simultaneously decreasing MycN, but increasing PTEN protein expression. Int J Oncol 49(4):1722–1730
Ren S, Liu J, Feng Y, Li Z, He L, Li L, Cao X, Wang Z, Zhang Y (2019) Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia. J Exp Clin Cancer Res 38(1):388
Feng S, Liu W, Bai X, Pan W, Jia Z, Zhang S, Zhu Y, Tan W (2019) LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer. Cancer Lett 465:105–117
Davidoff AM (2012) Neuroblastoma. Semin Pediatr Surg 21(1):2–14
Zhou X, Lu H, Li F, Han L, Zhang H, Jiang Z, Dong Q, Chen X (2020) LncRNA cancer susceptibility candidate (CASC7) upregulates phosphatase and tensin homolog by downregulating miR-10a to inhibit neuroblastoma cell proliferation. NeuroReport 31(5):381–386
Wen Y, Gong X, Dong Y, Tang C (2020) Long non coding RNA SNHG16 facilitates proliferation, migration, invasion and autophagy of neuroblastoma cells via sponging miR-542-3p and upregulating ATG5 expression. Onco Targets Ther 13:263–275
Liu H, Deng H, Zhao Y, Li C, Liang Y (2018) LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res 37(1):279
Liu Z, Ma C, Tang X, Tang Q, Lou L, Yu Y, Zheng F, Wu J, Yang X-B, Wang W, Hann SS (2019) The reciprocal interaction between LncRNA CCAT1 and miR-375-3p contribute to the downregulation of IRF5 gene expression by solasonine in HepG2 human hepatocellular carcinoma cells. Front Oncol 9:1081
Klat J, Mladenka A, Dvorackova J, Bajsova S, Simetka O (2019) L1CAM as a negative prognostic factor in endometrioid endometrial adenocarcinoma FIGO Stage IA-IB. Anticancer Res 39(1):421–424
Chen D-L, Zeng Z-L, Yang J, Ren C, Wang D-S, Wu W-J, Xu R-H (2013) L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. J Hematol Oncol 6:43
Liu X, Min S, Wu N, Liu H, Wang T, Li W, Shen Y, Zhao C, Wang H, Qian Z, Xu H, Chen Y, Wang X (2019) miR-193a-3p inhibition of the Slug activator PAK4 suppresses non-small cell lung cancer aggressiveness via the p53/Slug/L1CAM pathway. Cancer Lett 447:56–65
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no financial conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yang, H., Zhang, X., Zhao, Y. et al. Downregulation of lncRNA XIST Represses Tumor Growth and Boosts Radiosensitivity of Neuroblastoma via Modulation of the miR-375/L1CAM Axis. Neurochem Res 45, 2679–2690 (2020). https://doi.org/10.1007/s11064-020-03117-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-020-03117-9